MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/alz.70787

Медицинская библиотека · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

Seeking optimal repeated fluid biomarker assessments to enhance precision and statistical power in clinical trials: SLIM method.

Dodge Hiroko H, Chen Liu, Wu Chao-Yi, Cutter Gary, Bowman Gene L, Feldman Howard H, Arnold Steven E

СтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

INTRODUCTION

Plasma biomarkers are increasingly used as surrogate outcomes in clinical trials for Alzheimer's disease and related dementias (ADRD) due to their non-invasive nature. In early-phase trials designed to evaluate mechanisms of action and biological efficacy, assessing pre-post changes in plasma biomarkers within the same individuals - using a single-arm placebo lead-in design - offers a potentially cost-effective alternative to parallel-group designs by minimizing between-subject variability. However, plasma biomarkers are also subject to within-individual variability, which can obscure true treatment effects.

METHODS

One strategy to address this limitation is to collect repeated measures during each study period. This approach can improve measurement precision, enhance the signal-to-noise ratio, and increase statistical power, even with modest sample sizes.

RESULTS

We propose an innovative early-phase trial design, Single-arm Lead-In with Multiple measures (SLIM), which incorporates repeated biomarker assessments over a short follow-up period.

DISCUSSION: Using simulation studies, we demonstrate that the SLIM design can substantially reduce required sample sizes.

HIGHLIGHTS: SLIM involves repeated biomarker assessments during both the lead-in and post-treatment periods. It minimizes between-subject variability and improves the precision of within-subject estimates. It is well suited for early-phase, short-duration trials. It is not suitable for cognitive tests or other outcomes prone to practice or placebo effects. SLIM design can be an alternative to the traditional parallel design by reducing required sample sizes, thereby lowering the recruitment burden.

Для цитирования: Dodge Hiroko H, Chen Liu, Wu Chao-Yi, Cutter Gary, Bowman Gene L, Feldman Howard H, Arnold Steven E. Seeking optimal repeated fluid biomarker assessments to enhance precision and statistical power in clinical trials: SLIM method.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. DOI: 10.1002/alz.70787.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.